Credit Suisse’s Aratana Therapeutics, Inc. PETX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Sell |
-721,699
| Closed | -$3.72M | – | 4373 |
|
|
2019
Q2 | $3.72M | Buy |
721,699
+703,133
| +3,787% | +$3.16M | ﹤0.01% | 1982 |
|
|
2019
Q1 | $66K | Sell |
18,566
-221,636
| -92% | -$960K | ﹤0.01% | 3885 |
|
|
2018
Q4 | $1.47M | Buy |
+240,202
| New | +$1.47M | ﹤0.01% | 2477 |
|
|
2018
Q3 | – | Sell |
-14,527
| Closed | -$62K | – | 4120 |
|
|
2018
Q2 | $62K | Sell |
14,527
-17,378
| -54% | -$87.6K | ﹤0.01% | 3884 |
|
|
2018
Q1 | $140K | Buy |
31,905
+14,621
| +85% | +$65.2K | ﹤0.01% | 3757 |
|
|
2017
Q4 | $91K | Sell |
17,284
-10,995
| -39% | -$67.3K | ﹤0.01% | 3848 |
|
|
2017
Q3 | $173K | Buy |
28,279
+14,751
| +109% | +$93.4K | ﹤0.01% | 3972 |
|
|
2017
Q2 | $98K | Buy |
13,528
+1,495
| +12% | +$9.19K | ﹤0.01% | 3722 |
|
|
2017
Q1 | $63K | Sell |
12,033
-13,277
| -52% | -$89.7K | ﹤0.01% | 3727 |
|
|
2016
Q4 | $182K | Sell |
25,310
-42,689
| -63% | -$345K | ﹤0.01% | 3840 |
|
|
2016
Q3 | $636K | Buy |
67,999
+41,244
| +154% | +$343K | ﹤0.01% | 3282 |
|
|
2016
Q2 | $169K | Sell |
26,755
-305
| -1% | -$1.96K | ﹤0.01% | 3930 |
|
|
2016
Q1 | $149K | Sell |
27,060
-7,710
| -22% | -$29K | ﹤0.01% | 3757 |
|
|
2015
Q4 | $195K | Buy |
34,770
+18,962
| +120% | +$125K | ﹤0.01% | 3900 |
|
|
2015
Q3 | $133K | Sell |
15,808
-59,869
| -79% | -$1.01M | ﹤0.01% | 4053 |
|
|
2015
Q2 | $1.14M | Buy |
75,677
+3,747
| +5% | +$54.1K | ﹤0.01% | 3047 |
|
|
2015
Q1 | $1.15M | Buy |
71,930
+16,579
| +30% | +$295K | ﹤0.01% | 2856 |
|
|
2014
Q4 | $987K | Buy |
55,351
+30,210
| +120% | +$376K | ﹤0.01% | 3143 |
|
|
2014
Q3 | $253K | Sell |
25,141
-2,605
| -9% | -$31.6K | ﹤0.01% | 4017 |
|
|
2014
Q2 | $433K | Sell |
27,746
-82,194
| -75% | -$1.16M | ﹤0.01% | 3916 |
|
|
2014
Q1 | $2.04M | Buy |
+109,940
| New | +$2.2M | ﹤0.01% | 2491 |
|
Other funds holding PETX
Credit Suisse's PETX Position: Q3 2019 in Review
Credit Suisse sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 721,699 shares — an estimated $3.72M sold.
Credit Suisse first reported a position in PETX in Q1 2014 and held it in 21 quarters. The position peaked at $3.72M in Q2 2019. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.
- Credit Suisse reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
- Credit Suisse sold 721,699 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $3.72M.
- Credit Suisse first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 21 quarters.
- Credit Suisse's Aratana Therapeutics, Inc. position peaked at $3.72M in Q2 2019.
- 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.
Based on Credit Suisse's 13F filing for Q3 2019, filed 12 Nov 2019.